Core Viewpoint - Veradermics has announced the pricing of its upsized initial public offering (IPO) of 15,077,647 shares at $17.00 per share, aiming to raise approximately $256.3 million before expenses [1] Company Overview - Veradermics is a late clinical-stage biopharmaceutical company founded by dermatologists, focusing on innovative therapeutics for aesthetic and dermatological conditions [1] - The company is developing a focused portfolio of aesthetic dermatology product candidates, with a lead program, VDPHL01, targeting pattern hair loss [1] Initial Public Offering Details - The IPO is set to close on February 5, 2026, subject to customary closing conditions, with trading on the New York Stock Exchange expected to begin on February 4, 2026, under the ticker symbol "MANE" [1] - The underwriters have a 30-day option to purchase an additional 2,261,647 shares at the IPO price [1] Product Development - VDPHL01 is being developed as an oral, non-hormonal treatment for pattern hair loss, designed to enhance the effectiveness of minoxidil while minimizing cardiac risks [1] - The company has completed enrollment in its Phase 2/3 clinical trial for VDPHL01 for male pattern hair loss and is actively enrolling women for the first oral treatment trial for female pattern hair loss [2]

February 3, 2026 09:00 PM GMT China Equity Strategy | Asia Pacific Enhancing MSSBT – Capturing Full Alpha From Southbound Eligibility We introduce MSSBT V2, an enhanced forecast model aiming to capture greater alpha generation than V1 by incorporating Southbound deletions, in addition to inclusions. Backtesting shows a 93% hit ratio for our new deletion forecast model and an average 25% absolute return of our two-way trading strategy. Southbound inflows hitting record-highs with prominent impact on the Hong ...

Core Insights - Pharming is presenting its financial guidance for the year and highlighting its clinical stage pipeline programs during the 2026 Investor Day [1][2] - The company has evolved from a single asset company to a fast-growing biotech with two commercial assets experiencing double-digit growth and a late-stage pipeline with two programs each having over $1 billion sales potential [3] Financial Update - A short business and financial update will be provided, focusing on the financial guidance for the year [2] - The company emphasizes its growth trajectory and the potential of its pipeline programs [3] Pipeline Overview - The presentation will include two longer sessions dedicated to the pipeline, specifically on leniolisib for high prevalence primary immunodeficiencies (PIDs) and KL1333, napazimone [2]

Market Overview - Market indexes experienced a decline, particularly in high-growth tech stocks, with the Dow closing down 166 points (-0.34%), the S&P 500 down -0.84%, and the Nasdaq down -1.43% [1] - The small-cap Russell 2000 managed a slight gain of 8 points (+0.31%) [1] Employment Data - December JOLTS numbers were not released due to delays from a government shutdown, impacting the start of "Jobs Week" [2] - The upcoming ADP private-sector payrolls are expected to show a slight increase of 45,000 job gains, up 4,000 from the previous month [2] Earnings Reports - Advanced Micro Devices (AMD) reported Q4 earnings of $1.53 per share, surpassing expectations of $1.32 and previous year's $1.09, with revenues of $10.3 billion exceeding the anticipated $9.67 billion [3] - AMD's reported figures included a one-time gain of $390 million from chips sold to China, leading to initial skepticism and a 6% drop in shares during late trading [4] - Amgen (AMGN) reported earnings of $5.29 per share, exceeding expectations of $4.76, with revenues of $9.8 billion above the consensus of $9.47 billion, and product sales rose by 7% [5] - Chipotle (CMG) reported earnings of 25 cents per share, slightly beating expectations, with revenues of $2.98 billion surpassing the consensus of $2.96 billion; however, full-year same-store sales declined by 1.7%, marking the first contraction in nearly a decade [6]

Amgen (NasdaqGS:AMGN) Q4 2025 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsCasey Capparelli - VP of Investor RelationsDavid Amsellem - Managing DirectorJames Bradner - EVP of Research and DevelopmentMurdo Gordon - EVP of Global Commercial OperationsPeter Griffith - CFORobert Bradway - CEOTerence Flynn - Managing DirectorUmer Raffat - Managing DirectorYaron Werber - Managing DirectorConference Call ParticipantsAlex Hammond - AnalystChris Schott - AnalystCourtney Breen - Senior Research Ana ...

Market Overview - Stocks opened higher but experienced a significant plunge, ultimately closing down with the S&P 500 down about 0.9% and the Nasdaq down about 1.4% [6][7] - The Dow Jones Industrial Average also closed down about 0.4% while the Russell 2000 managed to close positive, up 0.3% [7] Sector Performance - The information technology sector was the biggest underperformer, down more than 2%, despite strong performance from companies like Palantir [8] - The energy sector saw a rise of more than 3% due to an increase in crude prices [9] Company Highlights - Palantir was a notable gainer, finishing the day up about 6.8% after a revenue forecast for fiscal 2026 that exceeded Wall Street expectations, projecting a 61% annual revenue increase [10] - Amgen reported a fourth-quarter adjusted EPS of $5.29, beating estimates of $4.71, indicating strong performance from its top drugs [12] - Walmart's stock closed up about 3%, marking a 14% increase year-to-date, attributed to its digital transformation and technology integration [14][15] Homebuilders - Homebuilders' stocks rose nearly 6% in the session, with the homebuilding index up about 2.5%, as they seek to develop affordable housing solutions [16] Notable Decliners - PayPal shares fell more than 20% following the announcement of a new CEO after a failed turnaround plan [17] - Novo Nordisk shares dropped over 14% after the company projected a sales decline of 5% to 13%, exceeding analyst expectations of a 1.4% decline [19] Earnings Reports - Silicon Labs stock surged about 39% in aftermarket trading due to reports of advanced talks with Texas Instruments [21] - Chubb's fourth-quarter net premiums came in at $13.13 billion, slightly above street estimates, while its combined ratio was 81.2%, below the expected 84% [27][28]

Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurological conditions, is pleased to announce that the Japan Patent Office has granted Japanese Patent No. 2022-554855, titled "Purine Compounds for Treating Disorders," covering composition of matter a ...

New York, New York--(Newsfile Corp. - February 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed can serve as primary basis of approval Rolling submission of the Biologic ...

Core Insights - Amgen Inc. is a leading biotechnology company engaged in innovative therapies and treatments, operating in a competitive landscape with peers like Biogen and Gilead Sciences [1] Investment Activity - Atlantic Union Bankshares Corp increased its investment in Amgen by 66.3% in Q3, now holding 17,698 shares valued at approximately $5 million, reflecting strong investor confidence [2] - Legacy Investment Solutions LLC and Evelyn Partners Investment Management LLP have acquired new stakes in Amgen, valued at around $27,000 and $32,000 respectively, indicating growing interest in the company's potential [3] - Quaker Wealth Management LLC increased its position in Amgen by 200% in Q2, further demonstrating the rising interest among investors [3] - Atle Fund Management AB reduced its holdings in Amgen by 42.2% in Q3, now owning 13,806 shares valued at approximately $3.9 million, showcasing varied investment strategies [4] Stock Performance - Amgen's stock is currently trading at $343.63, with a slight decrease of $1.16 or -0.34% today, and has experienced a 52-week high of $353.25 and a low of $261.43 [5] - The company maintains a solid market capitalization of approximately $185 billion, reinforcing its status as a key player in the biotechnology sector [5][6]